Forte Biosciences
Clinical-stage biopharma advancing dermatology with topical live biotherapeutics for inflammatory skin diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
* | N/A | $75.0m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Forte Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in dermatology. The company is pioneering a novel approach to treating inflammatory skin diseases through the development of FB 401, a topical live biotherapeutic. This product is designed to leverage the benefits of commensal bacteria, specifically targeting the skin's microbiome to address conditions such as atopic dermatitis. Forte Biosciences collaborates with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases to enhance its research and development efforts. The company operates within the biopharmaceutical market, focusing on patients with dermatological conditions. Its business model revolves around the development and commercialization of biotherapeutic solutions, generating revenue through product sales and potential partnerships. Forte Biosciences aims to transform the treatment landscape for skin diseases by harnessing the power of the skin's natural bacterial composition.
Keywords: biopharmaceutical, dermatology, inflammatory, skin disease, live biotherapeutic, microbiome, atopic dermatitis, commensal bacteria, NIH collaboration, FB 401.